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Non-ST segment elevation acute coronary
syndrome
P2Y12 receptor inhibitors
Percutaneous coronary interventionAims: Choosing an antiplatelet strategy in patients with non-ST segment elevation acute coronary syndrome
(NSTE-ACS) at high bleeding risk (HBR), undergoing post-percutaneous coronary intervention (PCI), is complex.
We used a unique open-source approach (crowdsourcing) to document if practices varied across a small, global
cross-section of antiplatelet prescribers in the post-PCI setting.
Methods and results: Five-hundred and fifty-nine professionals from 70 countries (the ‘crowd’) completed ques-
tionnaires containing single- or multi-option and free form questions regarding antiplatelet clinical practice in
post-PCI NSTE-ACS patients at HBR. A threshold of 75% defined ‘agreement’. There was strong agreement
favouring monotherapy with either aspirin or a P2Y12 inhibitor following initial DAPT, within the first year
(94%). No agreement was reached on the optimal duration of DAPT or choice of monotherapy: responses were
in equipoise for shorter (≤3 months, 51%) or longer (≥6 months, 46%) duration, and monotherapy choice (45%
aspirin; 53% P2Y12 inhibitor). Most respondents stated use of guideline-directed tools to assess risk, although
clinical judgement was preferred by 32% for assessing bleeding risk and by 46% for thrombotic risk.
Conclusion: The crowdsourcing methodology showed potential as a tool to assess current practice and variation
on a global scale and to achieve a broad demographic representation. These preliminary results indicate a high
degree of variation with respect to duration of DAPT, monotherapy drug of choice following DAPT and howhatt), jkaski@sgul.ac.uk (J.C. Kaski), sean.delaney@radcliffe-group.com, sean.delaney@radcliffe-group.com (S. Delaney),
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liability and freedom from bias of the data presented and their discussed interpretation.
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variation between key demographic groups.
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In patientswith non-ST segment elevation acute coronary syndrome
(NSTE-ACS) at high bleeding risk (HBR), current guidelines recommend
short duration of dual antiplatelet therapy (DAPT) with aspirin (ASA)
and the P2Y12 inhibitor clopidogrel, followed by monotherapy with
ASA thereafter, in the post percutaneous coronary intervention (PCI)
setting [1,2]. Randomised data from the CAPRIE trial, however, show
that clopidogrel monotherapy reduces hospitalisation for gastrointesti-
nal bleeding comparedwith ASA 325mg daily, and that gastrointestinal
bleeding is the most prevalent bleeding occurrence after PCI in the
outpatient setting [3]. In addition, since the publication of the most
recent set of guidelines (ESC in 2020), at least two independent meta-
analyses suggest that discontinuing ASA and continuing P2Y12 inhibitor
monotherapy after short duration DAPT, provides additional protection
against bleeding, without increasing thrombotic risk [4,5]. The choice of
antiplatelet strategy in theHBR population is therefore complicated and
despite growing evidence supporting the use of P2Y12 monotherapy
following initial DAPT [4–11], it is reasonable to expect that practice
may vary.
To gain insight into current practices and variation with respect to
antiplatelet therapy, we solicited input from a global audience of cardi-
ology professionals. Given the inherent selectivity of more traditional
survey methods, where participants are often predetermined, we
utilised an open-source approach, driven primarily through social
media. This novel ‘crowdsourcing’ methodology was chosen for its po-
tential to reach a broad audience of antiplatelet prescribers. Here, we
describe the findings of this preliminary study with respect to adher-
ence to guideline-directed care in NSTE-ACS patients at HBR, post-PCI,
from a small, global cohort of professionals.
2. Methods
The International Society of Cardiovascular Pharmacotherapy (ISCP)
and Radcliffe Medical Education developed a project to assess current
clinical practices in different World regions regarding the treatment of
NSTE-ACS patients at HBR, post-PCI. To this endwe appointed an expert
Steering Committee (SC) to preside over:
i) the desired characteristics of the crowd;
ii) the design of the questions;
iii) the interpretation of the results.2.1. Selection of steering committee members and the crowd
Fifteen SC members were invited to take part, based on their exper-
tise in the treatment of ACS and their contribution to medical literature
in this field. The following criteria were established to identify potential
SCmembers: known expertise in ACS patient management, PCI and use
of antiplatelet agents; >5 years' experience managing high volume ACS
patients; contribution to ACS and antithrombotic literature (at least one
co-authorship in a top-tier journal on the subject), and/or input into na-
tional or international clinical guidelines. Final selection was made
based on the willingness to take part in the creation of the survey and
the resulting publication.
2.2. Crowd characteristics
The selection process was designed to achieve representation across
geographies, practice seniority, nature of primary practice, specialty and2
sex. Prerequisite experience in prescribing antiplatelet therapy and fa-
miliarity with the topic was required to provide informed insight.
In line with the above, the SC provided the following guidance for
selecting individuals to take part:
Obligatory criteria
• Currently managing ACS patients
• Be a knowledgeable prescriber of antiplatelet therapy
• Be deemed to have a sound understanding of ACS/antiplatelet treat-
ment literature
Desirable criteria
• Be experienced in PCI procedures and post-PCI management
• Have involvement in clinical trials for antiplatelet therapy or related
therapy areas
• Be a local clinical decision maker/clinical policy shaper
• Be regarded as a key opinion leader in this field
Demographic questions were used to screen candidates for eligibil-
ity (see ‘Crowd registration’ for more detail); registrants were granted
access to the crowdsourcing platform if they satisfied the first two
clauses of the above obligatory criteria as aminimum; other criteria (se-
niority, geography, nature of primary practice) were used to estimate
how broad participation was.
2.3. Crowd recruitment
The crowd was recruited to take part both directly (through direct
email) and indirectly (through social media channels).
2.3.1. Direct recruitment
Contributions were sought from those whomet the defined criteria,
directly by members of the SC and representatives of the ISCP. The ISCP
is represented by an executive committee and board of directors,
representing countries from each major continent. Therefore, ISCP
members were encouraged to promote the project directly to known
professionals from their region.
In addition, Radcliffe Medical Education sent direct emails (total
269) to relevant participants fromRadcliffe Cardiology's global database
of health care professionals (HCPs); this approachwas used as a second-
ary tool to recruit from geographic regions where the SC or ISCP mem-
bers had no or low traction. Members of the editorial boards of the
Interventional Cardiology Review and European Cardiology Review
journals (both owned byRadcliffe Cardiology)were also invited to iden-
tify suitable crowdmembers (total 131 emails sent). Members of the SC
and the ISCPwith socialmedia profileswere encouraged to actively pro-
mote posts to their followers [12].
2.4. Crowd registration
See supplementarymaterials, S1 for details of the registration pro-
cess and demographic questions used for eligibility screening.
2.5. Sample size and representation
No upper limit was defined in line with the overall ambition of cap-
turing the prevailing insight and practices from a crowd representative
of a wide range of geographies and experience.
Fig. 1.Optimal monotherapy use after initial period of DAPT in NSTE-ACS patients at HBR:
Respondents were askedwhether they (A) agreedwith the use ofmonotherapy following
an initial period of DAPT (Yes, 94%; No, 6%), and (B) for those who agreed with the use of
monotherapy, what they felt the optimal duration of monotherapy was after initial
duration of DAPT (>12 months, 72%; 1–12 months, 22%; Other, 6%).
D.L. Bhatt, J.C. Kaski, S. Delaney et al. International Journal of Cardiology 337 (2021) 1–82.6. Data collection and statistical analysis
Participants answered questions housed on the crowdsourcing
platform, accessible via Google Chrome browser. Data analysis was per-
formed blinded to the respondents' demographics. Questions were of
three types:
i. Radio buttons or drop down for single option questions
ii. Multiple choice checkboxes for multi-selection questions
iii. Free form, where the respondents could type their answer.
For free form questions, all answers were combined into one for si-
multaneous review without statistical analysis. These were therefore
analysedmanually. For the remaining two types of questions, the server
computed the top voted answer, frequency of each chosen solution and
if the answer was a number, it computed: count, mean, standard devia-
tion (SD), min, 25%, 50%, 75% and max.
To see the questions, see supplementary materials, S2.
Features from the HyperText Markup Language (HTML) source, as
well as other raw data attributes, were extracted to perform quantita-
tive analyses on the responses.
In line with general accepted practice, a threshold of 75% was de-
fined as consensus on all single option questions [13].
3. Results
3.1. Crowd demographics
A total of 840 individuals registered to participate in the program,
559 of whom proceeded to complete the survey. Names and affiliations
of all collaborators are listed in Supplementary materials, S3. Among
registrants, five were rejected for failure to fulfil the eligibility criteria.
Completed surveys were submitted from individuals representing six
geographical regions and from across 70 countries. Country representa-
tion varied (range 1–47; Supplementarymaterial, S4). The experience
of respondents was measured by the number of reported ACS patients
treated/year with 13% reporting <50, 34% 50–200, 34% 200–500 and
19%>500. Among the individuals who completed the survey, 52% iden-
tified themselves as interventional cardiologists, 42% as general cardiol-
ogists, 3% as other prescriber and 3% as ‘Other’ (catheter laboratory
director, Coronary Care Unit cardiologist, general physician/doctor,
head of cardiac and vascular surgery, intensive care specialist); 64% of
responders reported more than 10 years' experience in practice and
59% working in a university/teaching hospital (Supplementary mate-
rials, S5). All respondents met the criteria of antiplatelet therapy
prescriber.
3.2. Ideal and current practice
Respondentswere initially asked about their ideal practice, irrespec-
tive of barriers to treatment such as access or reimbursement, local op-
erating procedures or recommendations from international or local
guidelines. Five-hundred and twenty-five (94%) respondents were in
favour of monotherapy following an initial period of DAPT in patients
assessed to be at HBR following PCI (Fig. 1A). In those who agreed
with the use of monotherapy in this context (monotherapy advocates),
the majority (n = 328, 72%) selected monotherapy use for longer than
12 months (Fig. 1B).Monotherapy advocates' preferred agent was split
roughly equally between ASA (n=212, 45%) and a P2Y12 inhibitor (n=
250, 53%). Respondents' choice of P2Y12 inhibitor as their ideal mono-
therapy agent was further split as follows: 127 (27%) clopidogrel; 104
(22%) ticagrelor; 19 (4%) prasugrel (Fig. 2A). Regional variation
displayed generally the same equipoise for ASA vs P2Y12 receptor inhib-
itor as observed at the global level, and across the experience level of re-
spondents (namely, length of time post-qualification [<5 years; 5–10
years; >10 years]).3
Monotherapy advocates did not agree on an optimal period of DAPT
following PCI, although 3 months (n = 204, 39%) was the most fre-
quently selected option (12 months [n = 115, 22%]; 6 months [n =
94, 18%]; 1 month [n = 63, 12%]; >12 months [n = 31, 6%]; other [n
= 16, 3%]), (Fig. 2B). Stated differently, 51% opted for ≤3 months, and
49% opted for ≥6 months DAPT duration.
The second section of the survey asked about current practices and
empirical use of guidelines. Of all respondents, 486 (87%) confirmed
that they carry out the approach that they had advocated as their per-
ceived ideal practice.3.3. Influences on current practice
Respondents were asked to select the factors that influenced
their antiplatelet preferences, including published guidelines and
randomised controlled trials. Respondentswere asked tomakemultiple
selections from a list identified by the SC that were relevant to their
decision-making. The ESC and ACC/AHA guidelines were the most
highly selected (n = 306, 61% and n = 166, 33%, respectively) [1,2].
This was followed by TWILIGHT (n = 121, 24%), STOP-DAPT 2
(n = 111, 22%) and GLOBAL LEADERS (n = 106, 21%) trials [6,7,14].
Other influential literature cited included the Japanese Circulation
Society guidance (n = 30, 6%) and the Brazilian Society of Cardiology
guidelines (n = 10, 2%).
Respondents were asked to rank factors impacting their choice of
P2Y12 inhibitor on a Likert scale (scale 1–5: 1, least influential; 5, most
influential). RCT evidence of safety was the most influential factor
Fig. 2. Optimal monotherapy choice in DAPT duration in NSTE-ACS patients at HBR:
Respondents were asked to select (A) ideal monotherapy choice irrespective of any
current barriers to access (ASA, 46%; clopidogrel, 26%; ticagrelor, 22%; prasugrel, 4%;
Other, 2%); (B) optimal period of DAPT (3 months, 39%; 12 months, 22%; 6 months, 18%;
1 month, 11%; >12 months, 5%; Other, 2%).
Fig. 3. Bleeding and thrombotic risk assessment practices: Respondents were askedwhich
method theymost frequently used for assessing (A) bleeding risk and (B) thrombotic risk
in NSTE-ACS patients following PCI.
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risk, thrombotic risk and patient related factors (all mean score 4.4 [SD
0.7]). This was followed by guideline recommendations (mean 4.2 [SD
0.7]), and then compliance with local protocols (mean 3.6 [SD 1.0]).
The least influential factor was cost/availability (mean 3.5 [SD 1.2]).
Clinical judgement over any single standardised score was the most
common way to assess bleeding and thrombotic risk (n = 178 [32%]
and n = 256 [46%], respectively, Fig. 3). Among the risk scores,
PRECISE-DAPT was the method most commonly used by respondents
to measure bleeding risk (n = 122, 22%). This was followed by DAPT
score (n=89, 16%), CRUSADE(n=78,14%), andARC-HBR (n=50,9%).
When asked to what extent their routine practice aligns with that of
the twomajor international guidelines on NSTE-ACS, 324 (58%) respon-
dents said their clinical practice ‘often’ followed ESC guidelines (the re-
maining stated ‘always’ n=61, 11%; ‘sometimes’ n=139, 25%; ‘rarely’
n=28, 5%; ‘never’ n=6, 1%; Fig. 4A). Two-hundred and forty (43%) re-
spondents said their clinical practice ‘often’ followed ACC/AHA guide-
lines (the remaining stated ‘always’ n = 45, 8%; ‘sometimes’ n = 178,
32%; ‘rarely’ n = 72, 13%; ‘never’ n = 22, 4%; Fig. 4B).4. Discussion
4.1. Crowdsourcing methodology
To our knowledge, this is the first use of a crowdsourcingmethodol-
ogy to assess practices with respect to antiplatelet therapy in NSTE-ACS.
It provides insight in an era where management of patients after ACS is
becoming increasingly complex, not least because of the rapidly advanc-
ing field of antithrombotic treatment and the lack of strong (class
I) guidance from guideline documents regarding the specific challenges
that HBR patients present to practitioners [1,2]. We document current4
practices from a global ‘crowd’ of practicing physicians, to derive insight
on the treatment of NSTE-ACS patients at HBR undergoing PCI.
Compared with a traditional prospective survey, where respondents
are typically identified in advance and their participation solicited, this
methodology provides a more democratic approach and thus a broad
view of current practices. Our respondents included practitioners from
six continents, 70 countries and represented a broad spectrum of expe-
rience and institution type (see Supplementarymaterials, S5). We be-
lieve this methodology, with its wide-ranging demographic uptake, is a
valuable tool, given its ability to rapidly map the degree of consensus or
controversy on clinically complex questions across the globe.4.2. Use of monotherapy and determining duration of DAPT
With respect to the use of monotherapy after an initial period of
DAPT in individuals at HBR, there was agreement on the use of mono-
therapy within 12months, with most respondents favouring a duration
beyond 12months. The crowd, however, did not agree on optimal dura-
tion of DAPT, although most (51%) did agree with treating for 1–3
months (aligning with current ESC recommendations) [1]; there was
also substantial support for 12 months DAPT (perhaps reflecting a
class IIb, level of evidence C recommendation from the ACC/AHA guide-
lines, albeit with no reference to HBR) [2]. This variation in practice is
not entirely surprising given that neither the ESC nor the ACC/AHA
guidelines provide class I recommendations in HBR patients, leaving
practitioners to determine DAPT duration based on their own estima-
tion of bleeding and thrombotic risk. Thus, determining risk is a critical
step in deciding the duration and choice of DAPT.
It is noteworthy that the European guidelines recommend PRECISE-
DAPT or ARC-HBR criteria to estimate bleeding risk [15–17]. Interest-
ingly, our results indicate that ARC-HBR was used by only 9% of
Fig. 4. Routine practice alignment with clinical practice guidelines: Respondents were
asked how often their routine practice, with respect to the use of antiplatelet therapy in
NSTE-ACS patients at HBR post-PCI, aligned with (A) current ESC recommendations and
(B) ACC/AHA recommendations.
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approach or the relative novelty of this system. A standout observation
in our datawas the degree towhich respondents did not use the recom-
mended bleeding or thrombotic risk assessments – clinical judgement
being used preferentially (Fig. 3). This approach may reflect the diver-
sity of bleeding and thrombotic risk scores and the lack of a universal,
validated tool. Of note, practice varied considerably in relation to guide-
line documents (Fig. 4).
4.3. Monotherapy choice and impact of clinical guidelines
Our findings also showed variation with respect to monotherapy
choice. Overall, respondents were equally likely to choose ASA or a
P2Y12 inhibitor. Interestingly, this equipoisemay reflect the coexistence
of two similar ECS 2020 guideline recommendations for either P2Y12 in-
hibitor discontinuation (IIa B) or ASA discontinuation (IIa A) [1]. ASA,
however, was the single most used antiplatelet agent overall.
In the 2020 ESC guidelines, several recent publications are consid-
ered in making the recommendation for shortening DAPT to 1–3
months [6,8,10,14]. The guidelines considered these study populations
to be low bleeding risk and low-to-intermediate ischaemic risk; for
them, a class I recommendation was made for the use of ticagrelor
monotherapy in low bleeding risk patients after 3 months DAPT, on
the basis of TWILIGHT [6]. In actual fact, the TWILIGHT study patients
were designated as either HBR or high ischaemic risk; this was defined
as the presence of at least one additional clinical feature and one angio-
graphic feature (see Table 1 for study design details). However, the
TWILIGHT cohort was not considered HBR in the ESC guidelines, in
part, owing to the one-year BARC 3 or 5 bleeding rates being below
the 4% cut-off (as defined in recent ARC-HBR criteria) [16] in both
monotherapy and DAPT arms. Thus, according to the 2020 ESC5
guidelines, in high or very high bleeding risk patients, monotherapy
after 1–3monthDAPT is either via ASA or clopidogrel (class IIa for either
options as per guideline Fig. 7) [1]. Interestingly, monotherapy with
clopidogrel or ticagrelor after 3–6 month DAPT is recommended with
equal strength (class IIa) “…depending on the balance between the
ischaemic and bleeding risk” (as per ESC guideline table entitled Recom-
mendations for post-interventional andmaintenance treatment in patients
with non-ST-segment elevation acute coronary syndrome) [1].
Since the publication of the 2020 ESC guidelines, there has been
growing support for the continuation of P2Y12 receptor inhibitors as
monotherapy in HBR patients [4,5,18]. The only large RCT evaluating a
potent P2Y12 inhibitor as monotherapy in a global population that in-
cluded some patients at HBR is TWILIGHT [6]. STOPDAPT-2 included a
share of HBR patients, but most were at low to intermediate thrombotic
and bleeding risk, so the overall significantly lower cardiovascular and
bleeding event ratewith P2Y12monotherapy comparedwith DAPT can-
not be extrapolated to entirely HBR populations [7] (see Table 1 for a
comparison of ACS trials with short and long-termDAPT arms). Overall,
recent meta-analyses and RCT data indicate that P2Y12 inhibitor mono-
therapy offers safety advantages over DAPT [ 4–6] and older data indi-
cate some ischaemic benefit of a P2Y12 inhibitor over ASA alone
[3,19]. Currently, there is a lack of prospective head-to-headmonother-
apy comparison in HBR patients (as judged by universally adopted
criteria) to recommend a specific antiplatelet agent over another.
Hence, for now, practicing clinicians should be guided by the strongest
randomised data, as well as guidelines. The strength of current
randomised data supports use of a potent P2Y12 inhibitor as monother-
apy, after 3 months of DAPT in HBR patients undergoing PCI.
5. Limitations
This study had some limitations. First, the social media-driven re-
cruitment means that the true denominator was unknown, therefore,
the generalisability of the findings remains uncertain. Second, given
the open-source design of the survey, we were unable to control for
over- and under-representation from key demographic groups. Third,
a true representative sample was not reached for Africa or Oceania
(eight and seven respondents, respectively); therefore, these areas
were excluded from regional assessments – but all regions and all coun-
tries were included in the overall analyses. Fourth, although social
media was used for data acquisition, a substantial proportion of re-
sponses was derived from direct recruitment from the expert Steering
Committee, members of the International Society of Cardiovascular
Pharmacotherapy and from Radcliffe Cardiology via their database. As
such, the true value of socialmedia as a recruitment driver cannot be de-
finitively measured in this sample. Fifth, because the overall number of
completionswere small (relative to the total global community of cardi-
ologists and other antiplatelet prescribers in ACS), we cannot take this
as conclusive evidence that the observed results are generalisable glob-
ally and therefore, we are unable to drawmeaningful conclusions across
different demographic or regional groups.
6. Conclusion
Crowdsourcing is a novel, open-source approach that has potential
to capture practices from a broad demographic. In the present study,
we used a combination of direct email and social media to drive regis-
trations, highlighting its potential as an accessible and easily executable
alternative to more traditional survey approaches, which rely on identi-
fying the participant base. The wide reach afforded by crowdsourcing
shows potential in providing democratic and agile mapping of crucial
clinical practice scenarios.
In this preliminary study, our chosen methodology highlighted a
high degree of variation with respect to the duration of DAPT, choice
of monotherapy and how bleeding and thrombotic risk are determined,
among a relatively small sample of cardiology professionals. Our results
Table 1
Summary of main trials in ACS comparing shorter duration DAPT (1–3 months) with longer term DAPT.
Twilight TICO Global leaders STOPDAPT-2 Smart-choice
P2Y12 inhibitor T T T C All (C, P, T)
Trial design n = 7119 n = 3056 n > 16,000 n = 3045 n = 2993
12 months: Open label,
randomised: Mono (T) vs
DAPT
12 months: Open label,
randomised: Mono (T) vs DAPT
24 months: Open label,
randomised: Mono T 23
months vs DAPT (C/T) 12
months, then ASA mono 12
months (C only in SIHD
with elective PCI)
12 months: Open label,
randomised: Mono (C) vs
DAPT






Primary Bleeding (BARC 2, 3, 5):
Superior in mono-T arm
(incl. stable and acute
sub-groups)






Superior in mono-T arm (incl. All
ACS sub-groups).
Composite all-cause
mortality or nonfatal MI:
Non-significant across
SIHD and ACS groups
Composite CV death, MI,
stroke, stent thrombosis or
TIMI major/minor bleed:












Major bleeding and major adverse
cardiac and cerebrovascular
events: 8 of 10 endpoints had no
significant difference; major

















BARC 3 or 5 bleeding; TIMI
major or minor bleeding;
GUSTO moderate, severe, or
life-threatening bleeding;
ISTH major bleeding:
Superior in mono-T arm
PCI indication














Bleeding risk: High Y: ≥ 1 additional clinical
feature and one
angiographic feature
associated with a high risk









Bleeding risk: Low Y: without increased risk of
bleeding
Y: no known overt major
bleeding, history
intracranial haemorrhage,












Thrombotic risk: Low Y: PARIS (48.6–50.2%);
CREDO (68.2–71.3)
Stent type
DES Y Y Y Y Y
BMS/other
Treatment duration post-PCI
1 month DAPT Y Y
3 months DAPT Y Y Y
Comparative period
(mono vs DAPT)
9 months 9 months 23 months (T or C) 9 9
Other differences
Ethnicity N America, Europe, Asia S Korea WW (18 countries) Japan Korea
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Table 1 (continued)
Twilight TICO Global leaders STOPDAPT-2 Smart-choice
Bleeding criteria Primary: BARC 2–5;
secondary: TIMI, GUSTO,
ISTH, BARC 3/5
TIMI BARC GUSTO BARC
ACS, acute coronary syndrome; BARC, Bleeding Academic Research Consortium; BMS, baremetal stent; C, clopidogrel; CREDO-Kyoto, Coronary Revascularization Demonstrating Outcome
Study in Kyoto; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; GUSTO, Global Utilization of Streptokinase and TPA for Occluded arteries; ISTH, International Society on Throm-
bosis and Haemostasis; MI, myocardial infarction; Mono, monotherapy; P, prasugrel; PARIS, Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients; PCI, percutaneous
coronary intervention; PRECISE-DAPT, Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy; SIHD, stable ischaemic
heart disease; STEMI, ST-elevation myocardial infarction; T, ticagrelor; TIMI, Thrombolysis In Myocardial Infarction.
D.L. Bhatt, J.C. Kaski, S. Delaney et al. International Journal of Cardiology 337 (2021) 1–8indicate that this sample embraced sources of literature outside of inter-
national guidelines and used their own clinical judgement to treat HBR
patients. The use of antiplatelet therapy in HBR individuals is not only
controversial, but merits careful consideration in future guidelines,
given multiple unanswered clinical questions that currently preclude
guidelines from forming class I recommendations.
As to how representative this present sample is of real-world prac-
tice remains to be determined; however, these largely hypothesis-
generating results highlight important practices that warrant validation
in larger studies. Subsequent studies on important participant sub-
groups are expected to yield a more detailed understanding on the
sources of variation and may reveal interesting differences between
key demographic groups according to speciality, experience level, and
region of practice.
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